Anti–PD-1 antibody with or without capecitabine as maintenance therapy after first-line therapy of recurrent or metastatic nasopharyngeal carcinoma
Anti-PD-1 antibody plus capecitabine maintenance therapy improved PFS with manageable toxicities in patients with RM-MPC following first-line immunochemotherapy, particularly in those with pre-treatment EBV DNA >12 400 copies/mL and undetectable post-treatment levels.
Authors
- Hai‐Qiang Mai (ORCID: https://orcid.org/0000-0001-6735-8670)
- Jiayi Shen (ORCID: https://orcid.org/0000-0002-7022-6940)
- Lin‐Quan Tang (ORCID: https://orcid.org/0000-0002-9613-7305)
- Jie Chen (ORCID: https://orcid.org/0000-0003-2151-5276)
- Shanshan Guo (ORCID: https://orcid.org/0000-0003-0393-2914)
- Yi-Fu Li (ORCID: https://orcid.org/0009-0004-7502-4784)
- Li-Ting Liu
- Hui Cheng (ORCID: https://orcid.org/0000-0003-1535-3979)
- Bowen Shen (ORCID: https://orcid.org/0000-0002-7913-4786)
- Pan Wang
- Jing‐Yun Peng
- Qiu-Yan Chen
- Xue-Song Sun
- Hao-Xiang Long
- Yu Chen (ORCID: https://orcid.org/0009-0009-4860-0316)
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-06-24
- DOI
- https://doi.org/10.1093/oncolo/oyaf188
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Sun Yat-sen University
- China Postdoctoral Science Foundation
- National Science and Technology Major Project
- National Key Research and Development Program of China
- Fundamental Research Funds for the Central Universities
- Basic and Applied Basic Research Foundation of Guangdong Province